{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:11:26Z","timestamp":1767186686601,"version":"build-2238731810"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T00:00:00Z","timestamp":1310601600000},"content-version":"vor","delay-in-days":194,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1590\/s1807-59322011000500014","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:02:33Z","timestamp":1761721353000},"page":"793-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes"],"prefix":"10.1016","volume":"66","author":[{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Lazarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"de Melo Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia Borgia Barbosa","family":"Pagnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Lorand-Metze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Ferreira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara T","family":"Olalla Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1590\/S1807-59322011000500014_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/asheducation-2004.1.297","article-title":"Myelodysplastic syndromes","author":"List","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1590\/S1807-59322011000500014_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/10428190009054877","article-title":"Excessive apoptosis in low risk myelodysplastic syndromes (MDS)","volume":"40","author":"Parker","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1590\/S1807-59322011000500014_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","author":"Parker","year":"2000","journal-title":"Blood"},{"key":"10.1590\/S1807-59322011000500014_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1590\/S1807-59322011000500014_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.bjc.6602970","article-title":"Mutation of the PIK3CA oncogene in human cancers","volume":"94","author":"Karakas","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1590\/S1807-59322011000500014_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1590\/S1807-59322011000500014_bib7","first-page":"60","article-title":"A missense TCF1 mutation in a patient with mody-3 and liver adenomatosis","volume":"65","author":"Lerario","year":"2009","journal-title":"Clinics"},{"key":"10.1590\/S1807-59322011000500014_bib8","first-page":"9","article-title":"Rubinstein-taybi syndrome: a female patient with a de novo reciprocal translocation t(2; 16)(q36.3; p13.3) and dysgranulopoiesis","volume":"65","author":"Torres","year":"2009","journal-title":"Clinics"},{"key":"10.1590\/S1807-59322011000500014_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S1807-59322009000900003","article-title":"Analysis of HFE and non-HFE gene mutations in Brazilian patients with hemochromatosis","volume":"64","author":"Bittencourt","year":"2009","journal-title":"Clinics"},{"key":"10.1590\/S1807-59322011000500014_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"231","key":"10.1590\/S1807-59322011000500014_bib11","doi-asserted-by":"crossref","first-page":"re7","DOI":"10.1126\/stke.2312004re7","article-title":"Mechanistic diversity of cytokine receptor signaling across cell membranes","volume":"2004","author":"Stroud","year":"2004","journal-title":"Sci STKE"},{"key":"10.1590\/S1807-59322011000500014_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0168-9525(00)89000-9","article-title":"Jaks and Stats in signaling by the cytokine receptor superfamily","volume":"11","author":"Ihle","year":"1995","journal-title":"Trends Genet"},{"key":"10.1590\/S1807-59322011000500014_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2006.04.011","article-title":"Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene","volume":"31","author":"Muller","year":"2007","journal-title":"Leuk Res"},{"key":"10.1590\/S1807-59322011000500014_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/1078-0432.CCR-05-2173","article-title":"PIK3CA mutations in head and neck squamous cell carcinoma","volume":"12","author":"Qiu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1590\/S1807-59322011000500014_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1073\/pnas.0705218104","article-title":"Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern","volume":"104","author":"Hafner","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1590\/S1807-59322011000500014_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms","volume":"105","author":"Zhao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1590\/S1807-59322011000500014_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/gcc.20540","article-title":"Rare PIK3CA hotspot mutations in carcinomas of the biliary tract","volume":"47","author":"Riener","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1590\/S1807-59322011000500014_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/asheducation-2006.1.240","article-title":"Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era","author":"Tefferi","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1590\/S1807-59322011000500014_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1073\/pnas.91.2.459","article-title":"STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells","volume":"91","author":"Small","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1590\/S1807-59322011000500014_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.onc.1210549","article-title":"The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence","volume":"26","author":"Cheng","year":"2007","journal-title":"Oncogene"},{"key":"10.1590\/S1807-59322011000500014_bib21","first-page":"84","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111:2776","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1590\/S1807-59322011000500014_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1590\/S1807-59322011000500014_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1590\/S1807-59322011000500014_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1590\/S1807-59322011000500014_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1309\/JT5BE2L1FGG8P8Y6","article-title":"Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia","volume":"126","author":"Lin","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1590\/S1807-59322011000500014_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2004-11-4430","article-title":"FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model","volume":"105","author":"Grundler","year":"2005","journal-title":"Blood"},{"key":"10.1590\/S1807-59322011000500014_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cancergencyto.2008.02.006","article-title":"FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia","volume":"183","author":"Pinheiro","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1590\/S1807-59322011000500014_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/jcp.2009.065904","article-title":"JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia","volume":"62","author":"Pich","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1590\/S1807-59322011000500014_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1590\/S1807-59322011000500014_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.blre.2010.01.002","article-title":"Significance of JAK2 and TET2 mutations in myelodysplastic syndromes","volume":"24","author":"Hellstrom-Lindberg","year":"2010","journal-title":"Blood Rev"},{"key":"10.1590\/S1807-59322011000500014_bib31","first-page":"45","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"key":"10.1590\/S1807-59322011000500014_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3324\/haematol.2009.010785","article-title":"Autocrine IGF-1\/IGF-1R signaling is responsible for constitutive PI3K\/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody","volume":"95","author":"Chapuis","year":"2010","journal-title":"Haematologica"},{"key":"10.1590\/S1807-59322011000500014_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2006-12-061283","article-title":"Constitutive phosphoinositide 3-kinase\/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients","volume":"110","author":"Tamburini","year":"2007","journal-title":"Blood"},{"key":"10.1590\/S1807-59322011000500014_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.leu.2404057","article-title":"Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients","volume":"20","author":"Nyakern","year":"2006","journal-title":"Leukemia"},{"key":"10.1590\/S1807-59322011000500014_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.onc.1209670","article-title":"A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16","volume":"25","author":"Billottet","year":"2006","journal-title":"Oncogene"},{"key":"10.1590\/S1807-59322011000500014_bib36","author":"Park"},{"key":"10.1590\/S1807-59322011000500014_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drup.2009.04.001","article-title":"FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML","volume":"12","author":"Weisberg","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1590\/S1807-59322011000500014_bib38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1158\/1078-0432.CCR-09-2836","article-title":"Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis","volume":"16","author":"Verstovsek","year":"2010","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1590\/s1807-59322011000700032","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000}}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222014296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222014296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:04:06Z","timestamp":1761721446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222014296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1807593222014296"],"URL":"https:\/\/doi.org\/10.1590\/s1807-59322011000500014","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1590\/S1807-59322011000500014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}